Your session is about to expire
← Back to Search
GCC19CART for Colorectal Cancer (CARAPIA-1 Trial)
CARAPIA-1 Trial Summary
This trial is testing a new drug for safety and effectiveness in people with a certain type of cancer that has returned or does not respond to treatment.
CARAPIA-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCARAPIA-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CARAPIA-1 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have any infections or other health issues that could affect my safety or the study's results.My diagnosis is metastatic colorectal cancer.I am over 18 years old.My cancer is in a place where treatment could harm an organ.I do not have a fever or an active infection needing treatment.I've had specific chemotherapy and targeted therapy for my advanced cancer, but it either stopped working or I couldn't tolerate it.My cancer is GCC positive based on a special tissue test.I have been told surgery cannot cure my condition.I have at least one tumor outside the brain that can be measured.My liver has fewer than 7 spots, with the biggest one smaller than 3 cm.
- Group 1: GCC19CART
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has GCC19CART received official authorization from the FDA?
"Our Power associates have deemed GCC19CART to possess a level of safety equivalent to 1 on the 3-point scale. This is because this Phase 1 trial has only limited information regarding its efficacy and security profile."
How many healthcare facilities have implemented this research protocol?
"In total, there are 6 medical centres participating in this study. These include the University of Michigan Comprehensive Cancer Center (Ann Arbor), Baylor Scott & White Research Institute (Dallas) and University of Colorado Hospital - Anschutz Cancer Pavilion (Aurora). Additionally, 3 other clinical trial sites are involved."
How many subjects have been enrolled in this investigation?
"This research requires 30 qualified patients to join. University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan and Baylor Scott & White Research Institute in Dallas, Texas are two possible sites for participants to consider."
Is recruitment ongoing for this research endeavor?
"According to records on clinicaltrials.gov, the medical trial is still in its recruitment phase. It was initially posted online August 1st of 2022 and revised recently on September 19th of that same year."
Who else is applying?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger